Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups.
about
Pharmacogenomic substudies of randomized controlled trials: consideration of safety outcomes.Interpreting the clinical utility of a pharmacogenomic marker based on observational association studies.Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia.
P2860
Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups.
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups.
@ast
Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups.
@en
Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups.
@nl
type
label
Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups.
@ast
Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups.
@en
Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups.
@nl
prefLabel
Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups.
@ast
Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups.
@en
Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups.
@nl
P2860
P1433
P1476
Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups.
@en
P2093
Brita A K Pekarsky
Michael Coory
P2860
P304
P356
10.1371/JOURNAL.PONE.0072256
P407
P577
2013-08-27T00:00:00Z